EP4267064A1 - Verbessertes pflaster - Google Patents
Verbessertes pflasterInfo
- Publication number
- EP4267064A1 EP4267064A1 EP21840153.7A EP21840153A EP4267064A1 EP 4267064 A1 EP4267064 A1 EP 4267064A1 EP 21840153 A EP21840153 A EP 21840153A EP 4267064 A1 EP4267064 A1 EP 4267064A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- adhesive
- patch
- plaster
- strips
- carrier material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011505 plaster Substances 0.000 title claims abstract description 35
- 239000000853 adhesive Substances 0.000 claims abstract description 46
- 230000001070 adhesive effect Effects 0.000 claims abstract description 45
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 14
- 239000002904 solvent Substances 0.000 claims abstract description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 9
- 239000011877 solvent mixture Substances 0.000 claims abstract description 9
- 239000003791 organic solvent mixture Substances 0.000 claims abstract description 8
- 229920000058 polyacrylate Polymers 0.000 claims abstract description 7
- 239000011248 coating agent Substances 0.000 claims abstract description 6
- 238000000576 coating method Methods 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 26
- 239000012876 carrier material Substances 0.000 claims description 23
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 20
- 208000003251 Pruritus Diseases 0.000 claims description 16
- 230000007803 itching Effects 0.000 claims description 15
- 230000008961 swelling Effects 0.000 claims description 12
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 8
- 230000001681 protective effect Effects 0.000 claims description 5
- 229920002301 cellulose acetate Polymers 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 229920002635 polyurethane Polymers 0.000 claims description 4
- 239000004814 polyurethane Substances 0.000 claims description 4
- 229920002955 Art silk Polymers 0.000 claims description 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003522 acrylic cement Substances 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 3
- 229920000297 Rayon Polymers 0.000 claims 1
- 239000002964 rayon Substances 0.000 claims 1
- 238000003848 UV Light-Curing Methods 0.000 abstract description 2
- 239000000758 substrate Substances 0.000 abstract 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 206010052428 Wound Diseases 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 10
- 230000035882 stress Effects 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 4
- 238000004080 punching Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003698 laser cutting Methods 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000003014 Bites and Stings Diseases 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
- A61F13/0289—Apparatus or processes for manufacturing adhesive dressings or bandages manufacturing of adhesive dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
- A61F13/0253—Adhesive bandages or dressings characterised by the skin-adhering layer characterized by the adhesive material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/0051—Plasters use for treating insect bite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00548—Plasters form or structure net
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00655—Plasters adhesive
- A61F2013/00659—Plasters adhesive polymeric base
- A61F2013/00663—Plasters adhesive polymeric base acrylic
Definitions
- the invention relates to the field of medical technology. More specifically, the invention relates to a method of making an improved patch, and a patch made by that method.
- Adhesive bandages also known as band-aids, band-aids or simply plasters, are well known in the art. They are used to cover small wounds. They protect them, for example to reduce the risk of contamination from impurities penetrating the wound and/or to prevent blood or wound fluid from escaping.
- Such a patch comprises a backing material that is typically rectangular, round, or oval. This is at least partially provided with an adhesive layer on the underside facing the wound. This has the task of releasably attaching the plaster to the skin surrounding the wound.
- the entire underside can also be self-adhesive. In the central area of the underside there is often a wound dressing that does not stick because it comes into contact with the actual wound.
- Plasters are also known which accelerate the healing of the covered wound by providing active ingredients in their wound dressing. These are gradually released and absorbed by the tissue through the wound.
- plasters are known whose wound dressing contains an active ingredient that prevents or reduces itching.
- a disadvantage of such patches is that their structure is more complex due to the multi-layer structure, and that the active ingredients are subject to a certain aging process and/or only to a certain, narrow extent Temperature range are storable.
- a further disadvantage is the fact that plasters of this type typically have to be packaged in a sterile manner in order to prevent infection through a contaminated plaster.
- the invention is therefore based on the object of providing a method for producing a plaster and a plaster produced using this method, which avoids the disadvantages of the prior art.
- the plaster should have a simple structure, and the effectiveness against the itching caused by insect bites should be largely independent of the storage conditions and the storage time.
- the invention relates to a method for producing a patch for reducing itching and/or swelling caused by insect bites.
- Such symptoms are particularly common side effects of such stings; although they are not normally dangerous, they are unpleasant and often require a relatively long time to subside.
- the itching leads to corresponding scratching reactions in the affected person, which further delays the healing of the swelling.
- the procedure includes the following steps : 1) Provision of an organic carrier material that can be coated with adhesive, preferably a carrier material comprising artificial silk, polyurethane or polyester.
- the backing material ensures the physical integrity of the patch. It preferably has a thickness in the range of 0.1 to 1.0 mm, preferably it has a thickness of 0.25 mm. It is particularly preferably elastic, with a modulus of elasticity (E modulus) which is preferably between 0.05 and 5 gigapascals and preferably between 0.5 and 2.0 gigapascals at a temperature of about 20° C. to 40° C. and most preferably at a temperature of about 22°C. 1.6 gigapascals.
- E modulus modulus of elasticity
- the solvent or solvent mixture is particularly preferably used in an amount of 40 to 55% by weight, based on the total weight of the acrylate adhesive.
- the organic solvent or solvent mixture contained in the adhesive preferably contains at least one solvent from the group consisting of ethyl acetate, 2-propanol, heptane, toluene and 2,4-pentanedione.
- the solvent is selected from the group consisting of isopropanol, heptane and ethyl acrylate.
- a solvent mixture is preferably used which consists of at least 90% by weight of ethyl acetate, 2-propanol and/or heptane.
- toluene and/or 2,4-pentanedione are used, their proportion in a solvent mixture is preferably not more than 10% by weight, the proportion of 2,4-pentanedione preferably being 0.3 to 5% by weight.
- a solvent mixture comprising isopropanol, heptane and ethyl acetate.
- a solvent mixture comprising isopropanol, heptane, ethyl acetate, toluene and 2,4-pentanedione.
- the solvent mixture contains 30 to 35% by weight isopropanol, 30 to 35% by weight heptane, 30 to 35% by weight ethyl acetate, 3 to 9.5% by weight toluene and 0.5 to 2% by weight 2,4-pentanedione.
- the acrylic polymer used according to the invention is preferably an acrylic copolymer, ie it is preferably made up of at least two different monomer units. Since it is used in solution, it is not a hot melt adhesive. There is no further restriction other than that the acrylic polymer is chosen so that it is completely soluble in the organic solvent or mixture of solvents. It has thus been shown that numerous acrylic polymers can be used according to the invention. The effect of the invention thus seems to be based on the interaction of all the features listed in the independent claim.
- the underside is the side that comes into contact with the skin during use.
- the purpose of the adhesive is to permanently but detachably connect the patch to the skin.
- "permanent" means a period of at least several hours up to several days.
- the adhesive can preferably be harmless with regard to prolonged contact with the skin.
- it should move away together with the carrier material without leaving any residue and without excessive tensile forces
- the underside of the carrier material is preferably completely coated with the adhesive.
- Suitable in this context means that the size of the patch exceeds the typical size of a swelling caused by an insect bite by at least 0.5 cm, preferably 1-2 cm. Accordingly, the size of the patch is at least 2x2 to 10x10 cm.
- the geometry can, for example, be rectangular, round or oval.
- Consfectioning means reducing or separating the plaster, which typically comes from a larger sheet or a wider or at least longer roll, to the desired external dimensions. This can be done, for example, by means of punching, mechanical cutting or laser cutting.
- the lattice structure can also be formed in that the strips are placed next to and on top of one another in a suitable manner, with them being correspondingly spaced apart from one another (additive method).
- the lattice structure may also be formed by deploying a plurality of randomly crossing strips, which may be linear or tortuous, and connecting them together at the crossing points; recesses are also formed in such a structure.
- the lattice structure leads to a reduction in the (global) modulus of elasticity of the patch, since the amount of material available in the corresponding direction is reduced, reduced by the width of the recesses in the direction of tension.
- the adhesive is applied to the carrier material at a temperature of 45° C. to 155° C. for a time of 5 s to 60 s. Under these conditions, the solvent present in the adhesive is almost completely, preferably completely, evaporated.
- the temperature is 90°C to 120°C, and more preferably 105°C.
- the application time is preferably 10 s to 30 s, and particularly preferably 20 s. Tests have surprisingly shown that a patch in which the adhesive has been applied with the above parameters has particularly good properties in terms of effectiveness against itching and/or swelling, since the mechanical properties of the patch are influenced in a particularly advantageous manner.
- the patch is also activated by repeated exposure of the underside to ultraviolet light.
- the irradiation preferably takes place at a wavelength of 100 to 380 nm.
- the cumulative irradiation time is preferably 0.01 to 2 s, and is particularly preferably carried out by means of several, in particular 3 to 5, consecutive short light pulses.
- the time between the pulses should preferably be measured in such a way that the temperature of the irradiated surface falls back to room temperature (21 °C + 5 °C).
- Irradiation with UV-A light (wavelength 380 nm to 315 nm) is preferably carried out first, and then with UV-B light (wavelength 315 nm to 280 nm) and/or UV-C light (wavelength 280 nm to 100 nm) .
- the irradiation takes place before or after the step of applying the adhesive.
- the underside of the carrier material is advantageously prepared for the application of the adhesive, which in turn has a positive effect on the mechanical properties of the patch.
- the adhesive itself and in particular its side intended for contact with the skin, is also changed in an advantageous manner, which also has a positive effect on the mechanical properties of the plaster, and in particular the "composite system" made of plaster and skin .
- the irradiation also has an effect on the stress pattern in the irradiated material. Irradiation with different wavelengths results in different penetration depths, which leads to different mechanical stress patterns at these depths.
- the mechanical properties of the plaster, as well as the "composite system” of plaster and skin, are improved in an optimal way.
- the result is an increased effectiveness of the plaster against itching and/or swelling when it has been stuck on the affected area .
- a patch produced using such a method is also suitable without such an agent for reducing itching and/or swelling caused by insect bites.
- neither drugs nor active ingredients are therefore added during production of the patch.
- the patch according to the invention therefore preferably also contains neither medicaments nor active ingredients.
- the invention thus avoids the disadvantages known from the prior art.
- the construction of the patch according to the invention is very simple due to its possible and particularly preferred single-layer structure, which simplifies production and reduces costs.
- Medicinal agents can be completely dispensed with. This means that the patch can be stored for up to 5 years before use. At the same time, it is significantly less sensitive to particularly high or low storage temperatures.
- the manufacturing method according to the invention improves the mechanical properties of the plaster and thus also its effectiveness against itching and/or swelling.
- the assembly step can be carried out before, after and during the step of producing the lattice structure. Assembling with a previous or subsequent production of the lattice structure (subtractive or additive structuring) causes the stresses induced by the processing to be shifted to the center of the pavement or towards the edge of the pavement. If the packaging and structuring are done at the same time, the tensions across the entire pavement are more balanced. The state of tension of the patch can also affect its attachment to the skin.
- the assembly step particularly preferably takes place before or after, ie not at the same time as, the structuring step, while the carrier material is coated with acrylate adhesive at any time Underside is arranged on a protective film.
- the associated mechanical processing is therefore two-stage in terms of time.
- the protective film which can be designed as peel-off paper, ensures that it is possible in a simple manner to first structure (i.e. to produce the recesses) and only then to assemble (i.e. to separate the patches from one another). ) , or the other way around .
- This treatment relaxes the areas (edges) already treated by cutting or punching.
- such a treatment does not take place again after the further step that follows, so that the stresses introduced by this further step continue to remain in the areas treated within the scope of this step.
- the patch has different internal stresses in its edge area (outer edges) than in its inner area (area of the recesses).
- the carrier material Since the carrier material is arranged on said protective film and remains in place until it is used, this ensures that the state of tension that has been created is maintained over the long term, since the carrier material does not move or z.
- the abovementioned activation is carried out by means of ultraviolet light by applying a first pulse with a length of 5 s ⁇ 1 s, followed by a first pause of 10 s ⁇ 2 s, and a second pulse with a length of 5 s ⁇ 1 s , followed by a second pause of 10 s ⁇ 2 s, and a third pulse with a length of 2.5 s ⁇ 0.5 s, onto which the adhesive layer already applied is delivered.
- the dose radiated onto the adhesive is preferably between 0.1 mJ/cm 2 and 1000 mJ/cm A 2 . It is particularly preferably between 20 mJ/cm 2 and 200 mJ/cm A 2 .
- the total irradiated dose should be between 0.1 mJ/cm 2 and 1000 mJ/cm A 2 . It is preferably between 5 and 500 mJ/cm 2 . It is particularly preferably between 20 mJ/cm 2 and 200 mJ/cm 2 . It is preferably 85 mJ/cm 2 ⁇ 15%.
- the lattice structure preferably consists of three vertical strips and preferably four horizontal strips. Each strip is approx. 3mm wide. The gaps between the strips have a width of 3 mm x 3 mm. This results in a total width of 21 mm and a length of 27 mm.
- Other preferred embodiments have dimensions of 36 mm x 28 mm with a strip width of 4 mm, and also 4 x 3 strips, or 52 mm x 44 mm with 6 x 5 strips.
- the vertical stripes and the horizontal stripes are at an angle of 90° to one another.
- the tool producing the recesses is placed accordingly (e.g. punching tool) or adjusted (e.g. cutting laser) so that the desired angles result.
- the recesses are then rectangular, such as square in particular.
- the advantage of this embodiment lies in a modulus of elasticity that is identical in the two main directions of pull. (The main directions of pull are two directions of pull lying in the plane of the paving and perpendicular to each other). This is advantageous in cases in which the plaster is to be applied to a skin area that stretches approximately equally in all directions, since the position of the plaster then plays no significant role.
- the vertical stripes and the horizontal stripes are at an angle of 7°, 30°, 42°, 45°, 60°, or 75° to one another.
- the advantage of this embodiment lies in a modulus of elasticity that is different in the two main directions of pull. In cases where the patch is to be applied to areas of skin with different levels of stretching, this embodiment can be used to achieve a mechanical reaction of different strength depending on the position on the skin.
- the lattice structure consists of three or more groups of strips each running parallel to one another. Each group encloses an angle to the remaining groups, so no group runs parallel to another group.
- the recesses then have - with 3 groups - a triangular shape, with 5 groups a pentagonal shape, etc. In the present case, 3 groups are particularly preferred.
- the advantage of this embodiment lies in the provision of 3 directions with a larger and 3 further directions with a lower modulus of elasticity, which can be desirable in certain applications.
- each strip ends in a free section on both sides.
- “Both sides” means that the beginning and end of the strip has a free section.
- the free sections result in a non-linear edge of the patch.
- the envelope of the patch is rectangular, the actual contour is defined by the free sections.
- this structure can be created by placing the outermost recesses in such a way that their outer edge coincides with the outer edge of the envelope of the patch, or by these recesses even being made to cover the outer edge .
- the advantage of such a design lies in the further improved interaction of the patch bonded to the skin .
- each free section are preferably at an angle of 90° to one another. Experiments have shown that edges shaped in this way achieve particularly good work results. The corners of the sections lead to a concentration of stresses when the patch is stuck on the skin, which further improves the effectiveness.
- each free section is tapered at an angle of 10° to 170°. This means that the sections form “arrows" pointing away from the center of the patch. The tips of these darts also cause stress concentration when the patch is adhered to the skin, further enhancing effectiveness.
- the ends of each free portion are rounded.
- the concentration of stresses described above can be disadvantageous, which can be avoided by rounded ends.
- the adhesive is applied under a pressure of 1 bar to 10 bar, preferably 2 bar to 6 bar, particularly preferably 3.057 bar to 5.095 bar, and most preferably 4.076 bar ⁇ 0.05 bar.
- a pressure of 1 bar to 10 bar, preferably 2 bar to 6 bar, particularly preferably 3.057 bar to 5.095 bar, and most preferably 4.076 bar ⁇ 0.05 bar.
- the pressure can also be provided by application in an atmosphere under said pressure. Applying the adhesive under said pressure leads to improved adhesion between it and the carrier material, which in turn has an advantageous effect on the mechanical properties of the patch.
- the adhesive is applied with a surface pressure of 200 kilopascals to 600 kilopascals, and preferably of 300 kilopascals to 500 kilopascals, and particularly preferably of 400 kilopascals, each ⁇ 1%.
- This surface pressure can be generated, for example, by means of a transfer plate after wetting the carrier material and maintained for at least 0.5 seconds, preferably at least 2 seconds, and particularly preferably 3-5 seconds. In this way, a good connection between the adhesive and the carrier material is achieved.
- the solvent is selected from the group consisting of isopropanol, heptane and ethyl acrylate.
- the invention also relates to a plaster for reducing itching and/or swelling caused by insect bites, the plaster is produced with a method according to the above description.
- the advantages resulting from the shaping and treatment during production are not repeated; instead, reference is made to the sections above.
- the backing material of the plaster particularly preferably comprises artificial silk, cellulose acetate, polyurethane or polyester.
- These materials are particularly skin-friendly, can be easily structured and treated using the method according to the invention, and have strengths of 0.1 and 1.0 denominated. g . suitable modulus of elasticity.
- Another benefit of cellulose acetate is its low moisture absorbency; thus , in web form , this material tends to build up static electricity . While this effect is generally undesirable, it is preferred in the case of the present patch, since it attaches itself to the skin almost automatically. The effect is more pronounced with thinner and thus more pliable material thicknesses.
- the proportion by weight of the backing material on the patch (without the protective layer) is preferably 50% to 70%, and the proportion by weight of the adhesive is 25% to 30%, more preferably 30% to 50%.
- the adhesive is an acrylic adhesive (also: acrylate adhesive).
- acrylic adhesive also: acrylate adhesive
- Such an adhesive has proven to be particularly skin-friendly; moreover, it can be applied well at the temperatures and pressures provided according to the invention.
- UV-curing has the above-mentioned advantages as a result of exposure to UV light and in connection with the method according to the invention.
- the acrylic adhesive preferably comprises the substances isopropanol, heptane and ethyl acetate as a solvent for the polyacrylate.
- An adhesive with these substances is particularly well suited to being connected to the carrier material by means of the method according to the invention.
- an adhesive comprising these components has turned out to be particularly skin-friendly and pleasant when it is removed again after the plaster has been used.
- FIG. 1 shows a schematic flow diagram relating to the method for producing an improved plaster
- FIG. 2 shows a schematic representation of an embodiment of a patch according to the invention
- FIG. 3 shows a schematic representation of a further embodiment of a patch according to the invention.
- FIG. 1 shows a schematic flow chart relating to the method for producing an improved plaster.
- the carrier material is provided.
- the adhesive is then applied to the underside of the carrier material, with the parameters specified in the figure with regard to temperature, time, pressure and surface pressure preferably being observed.
- Then follows the structuring (production of the lattice structure), as well as packaging (separation of the patches from the panel).
- the two last-mentioned steps can be carried out one after the other, but they can also be carried out simultaneously.
- the underside is activated before and/or after the coating by means of UV radiation.
- FIG. 2 shows a schematic representation of an embodiment of a plaster 1 according to the invention.
- this patch 1 has a lattice structure consisting of four vertical strips 2 and three horizontal strips 3 . Between the strips 2, 3 there are recesses 4 (only two provided with a reference number). The cutouts 4 result in the modulus of elasticity of the plaster being reduced (compared to a conventional plaster without cutouts, not shown).
- the vertical strips 2 and the horizontal strips 3 are at an angle 5 of 90° to one another.
- the recesses 4 are therefore rectangular, in this case square.
- the in this Fig. The embodiment shown has strips 2, 3 which end in free sections 6 on both sides (only two provided with reference numbers). The edges of each free section 6 are at an angle of 90° to one another (no reference number).
- FIG. 3 shows a schematic representation of another embodiment of a plaster 1 according to the invention. This differs from the one previously described in that the vertical strips 2 and the horizontal strips 3 are at an angle to one another which differs from 90°. In the present case, the angle 5 is approximately 68°. This results in different global moduli of elasticity for the two main directions of tension X, Y. In the main pulling direction Y, this is smaller than in the main pulling direction X. A load in the X-direction is primarily absorbed by the strips running in the X-direction, which continue to be loaded along their longitudinal axis. In the case of a load in the Y direction, however, the (tilted) vertical strips are no longer loaded in the direction of their longitudinal axis.
- the recesses were not made in the carrier material, for example by punching or laser cutting, but are formed by superimposing individual strips that are spaced apart from one another.
- This embodiment also has strips 2 , 3 which end in free sections 6 on both sides. However, the edges of each free section 6 here run at an angle of approx. 45°, which can lead to stress concentration at the tips after application of the patch 1 to the skin (not shown).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Manufacturing & Machinery (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102020134781.2A DE102020134781B4 (de) | 2020-12-22 | 2020-12-22 | Verbessertes Pflaster |
PCT/IB2021/062207 WO2022137177A1 (de) | 2020-12-22 | 2021-12-22 | Verbessertes pflaster |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4267064A1 true EP4267064A1 (de) | 2023-11-01 |
Family
ID=79287630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21840153.7A Pending EP4267064A1 (de) | 2020-12-22 | 2021-12-22 | Verbessertes pflaster |
Country Status (7)
Country | Link |
---|---|
US (1) | US20240050380A1 (de) |
EP (1) | EP4267064A1 (de) |
KR (1) | KR20230121116A (de) |
CN (1) | CN116669673A (de) |
AU (1) | AU2021405412A1 (de) |
DE (1) | DE102020134781B4 (de) |
WO (1) | WO2022137177A1 (de) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3121021A (en) * | 1960-04-18 | 1964-02-11 | Minnesota Mining & Mfg | Breathable surgical adhesive tapes |
DE10053563A1 (de) | 2000-10-27 | 2002-05-02 | Tesa Ag | Verfahren zur Herstellung von Acrylathaftklebemassen |
EP1996138B1 (de) | 2006-03-20 | 2016-11-02 | 3M Innovative Properties Company | Haftfolienartikel |
EP2985330B1 (de) * | 2010-03-09 | 2017-05-03 | Henkel IP & Holding GmbH | Kationische uv-vernetzbare acrylpolymere für druckempfindliche haftmittel |
BR112014003900A2 (pt) | 2011-09-01 | 2017-03-14 | 3M Innovative Properties Co | métodos para produção de uma camada ao menos parcialmente curada |
EP2756046A2 (de) | 2011-09-14 | 2014-07-23 | 3M Innovative Properties Company | Verfahren zur herstellung von haftmitteln ohne klebewirkung |
DE102014013448A1 (de) * | 2014-09-16 | 2016-03-17 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales Therapeutisches System umfassend Buprenorphin |
-
2020
- 2020-12-22 DE DE102020134781.2A patent/DE102020134781B4/de active Active
-
2021
- 2021-12-22 WO PCT/IB2021/062207 patent/WO2022137177A1/de active Application Filing
- 2021-12-22 US US18/258,297 patent/US20240050380A1/en active Pending
- 2021-12-22 CN CN202180086991.8A patent/CN116669673A/zh active Pending
- 2021-12-22 EP EP21840153.7A patent/EP4267064A1/de active Pending
- 2021-12-22 AU AU2021405412A patent/AU2021405412A1/en active Pending
- 2021-12-22 KR KR1020237023850A patent/KR20230121116A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
DE102020134781B4 (de) | 2023-01-05 |
DE102020134781A1 (de) | 2022-06-23 |
AU2021405412A1 (en) | 2023-07-06 |
US20240050380A1 (en) | 2024-02-15 |
KR20230121116A (ko) | 2023-08-17 |
WO2022137177A1 (de) | 2022-06-30 |
CN116669673A (zh) | 2023-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2688533B1 (de) | Primärauflage für die feuchte wundversorgung und verfahren zu deren herstellung | |
EP2858613B1 (de) | Medizinprodukt zur versorgung eines individuums | |
WO1995031188A1 (de) | Hydrophile haftschmelzkleber | |
WO1999012529A2 (de) | Transdermales therapeutisches system mit haftklebender reservoirschicht und unidirektional elastischer rückschicht | |
EP0002509A1 (de) | Verband zur Aufbringung auf Wunden | |
DE69907802T2 (de) | Thermisch wirkende Pflaster und seiner Verwendung | |
WO1994008571A2 (de) | Pflaster zur transdermalen verabreichung von flüchtigen, pharmazeutisch wirksamen, chemisch basischen inhaltsstoffen und verfahren zu seiner herstellung | |
EP0966273B1 (de) | Transdermales oder topisches pflastersystem mit polyacrylatmatrix mit verbesserten physikalischen eigenschaften | |
DE60215347T2 (de) | Wundverband | |
DE69216963T2 (de) | Acrylgel und dieses enthaltende Zusammensetzung zur perkutanen Absorption | |
DE4336299A1 (de) | Gelkörper zur percutanen Verabreichung, insbesondere von Medikamenten | |
DE102020134781B4 (de) | Verbessertes Pflaster | |
EP1732487B1 (de) | Medizinisches pflaster zur anwendung auf der haut | |
DE202020107505U1 (de) | Verbessertes Pflaster | |
EP3145501B1 (de) | Lavendelöl enthaltendes transdermales therapeutisches system | |
DE9400844U1 (de) | Testpflaster zur epicutanen Hauttestung | |
DE2045941A1 (de) | Mittel zum Zusammenfügen und Zusammenhalten der Hautränder von Schnitten oder Einschnitten in der Haut eines menschlichen oder tierischen Körpers | |
DE102022116007B3 (de) | Vorrichtung zur lösbaren Anbringung auf der Haut einer Person | |
EP1267845B1 (de) | Wirkstoffpflaster | |
DD279818A1 (de) | Verfahren zur herstellung eines medizinischen pflasters | |
WO2004110323A1 (de) | Pflaster-vorrichtung | |
EP1107742A1 (de) | Arzneistoffhaltiges pflaster mit drei funktionalen schichten | |
DE202015100021U1 (de) | Aufbau eines Pflasters zur Wundheilung mit desinfizierender Wirkung | |
DE202006007572U1 (de) | Transdermales Pflaster | |
DE202015009065U1 (de) | Klebeband enthaltend Beinwell bzw. Beinwellwurzelextrakt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230628 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240809 |